Expired activity
Please go to the PowerPak homepage and select a course.

Individualizing Treatment Regimens for Hepatitis C:
A 2016 Update for Specialty Pharmacists

Provided by The University of Tennessee College of Pharmacy, in cooperation with ASiM.
Supported by an educational grant from Merck & Co Inc.


Since its official identification in 1989, the hepatitis C virus (HCV) has grown from relative obscurity to the most commonly transmitted blood-borne pathogen in the world. In the United States, current estimates indicate that approximately 4.6 million people have antibodies against HCV, and 3.5 million patients are chronically infected. Despite a stable disease rate, the direct healthcare costs for treating patients with HCV are expected to increase from $6.5 billion per year at present to nearly $10 billion per year within the next decade. Therefore, determining the cost-effectiveness of individual treatment regimens has become an increasingly important component of specific regimen recommendations. This archived symposium will highlight new and emerging opportunities for individualizing HCV treatment and management based on drug efficacy and safety, disease-related factors, patient comorbidities, and other considerations. Pharmacist-led strategies for supporting treatment adherence, navigating cost issues, and ensuring optimal patient outcomes in the era of attainable HCV therapies will be reviewed.


Managed care and specialty pharmacists will gain an improved understanding of evidence-based options for individualizing HCV treatment, as well as strategies for improving medication access, adherence, and safety, thus optimizing pharmaceutical care.


This activity is designed for specialty pharmacists. No prerequisites required. No prerequisites required.


The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:

  • ASSESS individualized treatment plans for HCV treatment and associated monitoring parameters.
  • RECOGNIZE patient-specific disease state complications relevant to drug therapy selection and modifications.
  • EVALUATE benefits, risk, and characteristics of drugs in the HCV pipeline.
  • RECOMMEND strategies to cope with social challenges and increase patient adherence with therapy.


acpeThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based program will provide a statement for 1.5 contact hours of credit (0.150 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument with a score of at least 70%. UAN: 0064-0000-16-213-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days.  It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE Monitor.

Type of Activity: Application

Published: November 30, 2016
Expires: November 30, 2017

Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 90 minutes


Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.


As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:


Pamela S. Belperio, PharmD, BCPS, AAHIVE
National Public Health Clinical Pharmacist
VA Office of Public Health/Population Health
Department of Veterans Affairs
Los Angeles, California 
Dr Belperio reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Brittany Mills, PharmD, MBA, BCACP, AAHIVP 
Clinical Pharmacist, Pharmacy Manager
Walgreens at Howard Brown Health Center
Chicago, Illinois
Dr Mills reports having no relevant financial or advisory relationships with corporate organizations related to this activity.


In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.


The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.


A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.


The following is an archived symposium designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.


Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5


  • Welcome and Conference Goals
    Pamela S. Belperio, PharmD, BCPS, AAHIVE
  • Current Status of HCV Therapy
    Brittany Mills, PharmD, MBA, BCACP, AAHIVP
  • Considerations for Individualized Treatment
    Brittany Mills, PharmD, MBA, BCACP, AAHIVP
  • Latest Guideline-Based Therapy Recommendations
    Pamela S. Belperio, PharmD, BCPS, AAHIVE
  • Emerging Treatment Options and Trends
    Pamela S. Belperio, PharmD, BCPS, AAHIVE
  • Pharmacist-Led Education Strategies
    Brittany Mills, PharmD, MBA, BCACP, AAHIVP
  • Closing Remarks and Educational Outcomes Activity
    Pamela S. Belperio, PharmD, BCPS, AAHIVE

What you are about to see is a previously recorded live meeting. Please note that only "home study"
credit will be awarded for participating in this archived presentation.

No "live" credits are available.